Tech Company Financing Transactions
DeuteRx Funding Round
DeuteRx, based in Andover, secured $2.8 million from private investors.
Transaction Overview
Company Name
Announced On
10/1/2015
Transaction Type
Venture Equity
Amount
$2,800,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds for the advancement of its lead program, DRX-065, into human clinical trials for the treatment of adrenoleukodystrophy (ALD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
300 Brickstone Sq. 201
Andover, MA 01810
USA
Andover, MA 01810
USA
Phone
Website
Email Address
Not Recorded
Overview
DeuteRx is a research and development-focused biotechnology company dedicated to improving racemic small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sheila DeWitt
VP - R & D
Vincent Jacques
Browse more venture capital transactions:
Prev: 10/1/2015: Neuromod Devices venture capital transaction
Next: 10/1/2015: OpenGamma venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. VC investment data records on this site are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs